Shares of SenesTech Inc (NASDAQ:SNES) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $2.50 for the company and are forecasting that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 143 out of 255 based on the ratings given to related companies.
Separately, Zacks Investment Research cut SenesTech from a “hold” rating to a “sell” rating in a report on Thursday, August 30th.
Shares of NASDAQ SNES opened at $0.71 on Friday. The firm has a market capitalization of $16.16 million, a price-to-earnings ratio of -0.63 and a beta of 2.15. The company has a quick ratio of 4.07, a current ratio of 5.05 and a debt-to-equity ratio of 0.05. SenesTech has a fifty-two week low of $0.30 and a fifty-two week high of $3.87.
SenesTech (NASDAQ:SNES) last announced its quarterly earnings data on Monday, August 13th. The company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.12). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.40 million. SenesTech had a negative net margin of 13,362.22% and a negative return on equity of 214.75%. As a group, equities research analysts forecast that SenesTech will post -0.61 EPS for the current fiscal year.
A hedge fund recently bought a new stake in SenesTech stock. Bank of Montreal Can acquired a new stake in SenesTech Inc (NASDAQ:SNES) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 80,000 shares of the company’s stock, valued at approximately $131,000. Bank of Montreal Can owned approximately 0.48% of SenesTech at the end of the most recent reporting period. 8.11% of the stock is currently owned by institutional investors and hedge funds.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Recommended Story: How Investors Use a Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.